CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference
CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference
LA JOLLA, Calif., Sept. 3, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will participate in a presentation at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 7:00 a.m. ET/ 4:00 a.m. PT.
2024年9月3日-CalciMedica Inc.（「CalciMedica」）（納斯達克：CALC）是一家臨床階段的生物製藥公司，專注於開發用於急性和慢性炎症和免疫疾病的新型鈣釋放激活鈣（CRAC）通道抑制療法。 CRAC）通道抑制融合在一起，幫助改善炎症和免疫疾病患者的病情。 這家公司今天宣佈，首席執行官Rachel Leheny博士將於2024年9月9日星期一參加H.C. Wainwright第26屆年度全球投資會議上的演講，時間爲美東時間上午7:00 / 美太時間上午4:00。
A live webcast of the presentation can be accessed in the "Upcoming Events" section of CalciMedica's IR website at . A replay of the webcast will be archived on the Company's website for 90 days.
可以在CalciMedica的投資者關係（IR）網站的「即將發生的事件」一欄中訪問演講的現場網絡廣播。 網絡廣播的回放將在公司網站上存檔90天。
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced topline data for a Phase 2b trial (called CARPO – NCT04681066) in patients with AP with SIRS and completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with AKI with associated AHRF with data expected in 2025 and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in patients with AIPT with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit .
CalciMedica是一家致力於開發新型CRAC通道抑制劑治療炎症和免疫疾病的臨床生物製藥公司。CalciMedica的專有技術針對CRAC通道的抑制作用可調節免疫反應，從而保護組織細胞，有潛力在當前沒有已批准療法的危及生命的炎症和免疫性疾病中提供治療效益。CalciMedica的主要產品候選藥物Auxora已經在多項完成的療效性臨床試驗中展現出積極和一致的臨床結果，對於第二期臨床試驗具有參考意義。奇泊 -NCT04681066）和冠狀病毒性肺炎患者的第2期臨床試驗（名爲CARDEA -NCT04345614）已經完成，繼續支持正在進行的第1/2AIPT研究（名爲CRSPA -NCT04195347），預計在2025年公佈數據，並已啓動其第2項研究（名爲KOURAGE -NCT06374797），預計在2025年公佈基於與AHRF相關的AKI的數據。 CalciMedica由來自Torrey Pines Therapeutics和哈佛CBR生物醫學研究所的科學家創立，總部位於加利福尼亞州拉荷亞。有關更多信息，請訪問。
CalciMedica是一家臨床階段的生物製藥公司，專注於開發用於炎症和免疫疾病的新型CRAC（鈣釋放激活鈣）通道抑制療法。 CalciMedica的專有技術可以通過抑制CRAC通道來調節免疫反應，並保護組織細胞免受損傷，具有潛在的治療優勢，可用於目前尚無批准療法的危及生命的炎症和免疫疾病。 CalciMedica的首個產品候選藥物Auxora在多項已完成的功效臨床試驗中表現出積極且一致的臨床結果。 CalciMedica已經公佈了一項針對與SIRS合併的AP患者的第2期試驗（稱爲CARPO - NCT04681066）的前線數據，並已完成了針對COVID肺炎患者的第2期試驗（稱爲CARDEA - NCT04345614）。 2025年，該公司正在進行一項針對與關聯的AHRF患者的第2期試驗（稱爲KOURAGE - NCT06374797），並持續支持正在進行的一項針對AIPt患者的第1/2期試驗（稱爲CRSPA - NCT04195347）結果預期將於2025年公佈。 CalciMedica由Torrey Pines Therapeutics和Harvard CBR Institute for Biomedical Research的科學家創立，並設在加利福尼亞州拉霍亞。 有關更多信息，請訪問。
CalciMedica Contact:
CalciMedica聯繫方式：Sarah Sutton / Kevin Murphy
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
[email protected]
(212) 600-1902
投資者和媒體
阿哥特合夥人。
來源：CalciMedica, Inc.
[email protected]
（212）600-1902
SOURCE CalciMedica, Inc.
源自CalciMedica，Inc。
譯文內容由第三人軟體翻譯。